

Commission Directive (EU) 2017/1572 of 15 September 2017 supplementing Directive 2001/83/EC of the European Parliament and of the Council as regards the principles and guidelines of good manufacturing practice for medicinal products for human use (Text with EEA relevance)

Article 1	Subject-matter
Article 2	Definitions
Article 3	Inspections
Article 4	Conformity with good manufacturing practice
Article 5	Compliance with marketing authorisation
Article 6	Pharmaceutical quality system
Article 7	Personnel
Article 8	Premises and equipment
Article 9	Documentation
Article 10	Production
Article 11	Quality control
Article 12	Outsourced operations
Article 13	Complaints and product recall
Article 14	Self-inspection
Article 15	Repeal of Directive 2003/94/EC
Article 16	Transposition
Article 17	Entry into force
Article 18	Addressees
	Signature

ANNEX

Correlation table

***Status:** EU Directives are being published on this site to aid cross referencing from UK legislation. After
IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.*

- (1) [OJ L 311, 28.11.2001, p. 67.](#)
- (2) Commission Directive 2003/94/EC of 8 October 2003 laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use ([OJ L 262, 14.10.2003, p. 22](#)).
- (3) Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC ([OJ L 158, 27.5.2014, p. 1](#)).
- (4) Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004 ([OJ L 324, 10.12.2007, p. 121](#)).